Skip to main content

Interim reports

2017-08-08
OUR THREE LARGEST BRANDS ARE DEVELOPING WELL "Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented," says Peter Wolpert, CEO Moberg Pharma.
2017-05-09
CONTINUED STRONG GROWTH IN EBITDA  
2017-02-14
EBITDA TRIPLED IN THE FOURTH QUARTER